文献速递帕金森病与运动障碍认知障碍与痴呆

帕金森病中α-突触核蛋白种子扩增试验动力学指标的诊断与预后价值:纵向队列研究

Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study.
PubMed 文献 · Lancet Neurol · 2025-01-01

这项纵向队列研究分析了三个队列共1631名参与者,评估脑脊液α-突触核蛋白种子扩增试验(SAA)动力学指标的诊断与预后价值。研究发现SAA动力学指标有助于鉴别帕金森病与进行性核上性麻痹伴路易体共病理,且较快的种子扩增动力学见于GBA1相关帕金森病并独立于阿尔茨海默病共病理预测认知下降。

要点

  • SAA动力学指标有助于鉴别帕金森病与进行性核上性麻痹伴路易体共病理。
  • GBA1相关帕金森病较散发性帕金森病种子扩增动力学更快。
  • 基线TTT可预测帕金森病认知下降,独立于阿尔茨海默病共病理。

核心结论

  • 评估α-突触核蛋白SAA动力学指标可能有助于帕金森病与进行性核上性麻痹伴路易体共病理的鉴别诊断。
  • 较快的种子扩增动力学见于GBA1相关帕金森病,并独立于阿尔茨海默病共病理预测帕金森病认知下降。

研究设计与样本

  • 纵向队列研究,纳入英国帕金森综合征队列、PPMI国际观察性研究和蒂宾根帕金森病队列,共分析1631名参与者。
  • 英国队列新生成数据:帕金森病66例,进行性核上性麻痹52例,对照9例;PPMI既往数据:帕金森病1036例,对照239例;蒂宾根队列:帕金森病229例。

主要发现

  • 英国帕金森综合征队列中,α-突触核蛋白SAA在66例帕金森病样本中阳性63例(96%),在52例进行性核上性麻痹样本中阳性8例(15%)。
  • 8例SAA阳性进行性核上性麻痹样本中6例(75%)具有独特的低而慢的种子扩增动力学(低MaxThT和高TTT),作为路易体共病理标志。

临床怎么用

  • 脑脊液α-突触核蛋白SAA动力学指标可用于辅助鉴别帕金森病与进行性核上性麻痹伴路易体共病理。
  • 基线TTT有助于预测帕金森病患者的认知下降风险,且独立于阿尔茨海默病共病理。
  • GBA1相关帕金森病患者种子扩增动力学更快,提示可根据动力学特征识别特定遗传亚型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: α-synuclein seed amplification assay (SAA) positivity has been proposed as a diagnostic biomarker for Parkinson's disease. However, studies of the prognostic value of this biomarker have been limited to small, single-centre studies over short follow-up periods. We aimed to assess the diagnostic and prognostic value of quantitative CSF α-synuclein SAA kinetic measures in Parkinson's disease. METHODS: In this longitudinal cohort study, we collected and analysed data from participants with Parkinson's disease, progressive supranuclear palsy, and healthy controls enrolled in three cohorts: the UK parkinsonism cohort, the Parkinson's Progression Markers Initiative (PPMI) international observational study, and the Tübingen Parkinson's disease cohort. Baseline CSF α-synuclein SAA data and longitudinal clinical data were collected between Jan 1, 2005, and Nov 1, 2023. The following seeding kinetic measures were calculated from the α-synuclein SAA curve for each SAA-positive sample: time to threshold (TTT) for a positive SAA result; maximum Thioflavin T fluorescence during the reaction time (MaxThT); and area under the fluorescence curve during the reaction time (AUC). We compared seeding kinetic measures between sporadic Parkinson's disease and progressive supranuclear palsy, and between sporadic Parkinson's disease and monogenic Parkinson's disease. We used time-to-event analyses to assess the ability of α-synuclein SAA kinetic measures to predict an unfavourable outcome in Parkinson's disease, adjusting for sex, age, and disease duration at SAA testing. FINDINGS: We analysed data from 1631 participants: newly generated data from the UK parkinsonism cohort (Parkinson's disease, n=66; progressive supranuclear palsy, n=52; controls, n=9) and previously generated data from the PPMI (Parkinson's disease, n=1036; controls, n=239) and Tübingen (Parkinson's disease, n=229) cohorts. In the UK parkinsonism cohort, α-synuclein SAA was positive in 63 (96%) of 66 Parkinson's disease samples and eight (15%) of 52 progressive supranuclear palsy samples, with six (75%) of eight positive progressive supranuclear palsy samples having distinct low and slow seeding kinetics (low MaxThT and high TTT) as a marker of Lewy body co-pathology. TTT was faster in GBA1-associated Parkinson's disease compared with sporadic Parkinson's disease in both the PPMI (p=0·04) and Tübingen (p=0·01) cohorts. In the PPMI cohort, after excluding individuals who had an unfavourable outcome at the time of baseline SAA testing, an unfavourable outcome was observed in 593 (73%) of 810 participants with α-synuclein SAA-positive Parkinson's disease during a median follow-up period of 4·5 years (IQR 2-9). TTT at baseline predicted only cognitive decline (Montreal Cognitive Assessment score ≤21) as a component of an unfavourable outcome in Parkinson's disease in both the PPMI (n=824, hazard ratio [HR] 2·36 [95% CI 1·60-3·46], p=0·001) and Tübingen (n=135, 2·17 [1·07-4·41], p=0·03) cohorts. TTT also predicted cognitive decline in a subgroup of participants with Parkinson's disease in the PPMI cohort who were Alzheimer's disease biomarker negative (n=355, HR 1·80 [95% CI 1·03-3·18], p=0·04). INTERPRETATION: Assessing α-synuclein SAA kinetic measures might aid in the diagnostic differentiation of Parkinson's disease from progressive supranuclear palsy with Lewy body co-pathology. Furthermore, faster seeding kinetics are found in GBA1-Parkinson's disease and predict cognitive decline in Parkinson's disease independently of Alzheimer's disease co-pathology. FUNDING: Medical Research Council, PSP Association. COPYRIGHT: © 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Orrú CD, Vaughan DP, Vijiaratnam N, et al. Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study. Lancet Neurol. 2025. PMID: 40541208. doi:10.1016/S1474-4422(25)00157-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。